IN PHASE 3 TRIALS

Survodutide

Boehringer Ingelheim and Zealand Pharma's GLP-1/glucagon dual agonist. Phase 3 for chronic weight management. FDA Fast Track designation for MASH (the liver-disease use case where the glucagon-receptor mechanism could really matter).

The 30-second read

Survodutide is a synthetic peptide that activates GLP-1 and glucagon receptors, same dual-mechanism strategy as Mazdutide but in Western development. Boehringer Ingelheim and Zealand Pharma run the program. Phase 2 data in chronic weight management produced about 19% mean weight loss over 46 weeks at the highest dose. Phase 3 (SYNCHRONIZE program) is in progress for both weight management and MASH (metabolic dysfunction-associated steatohepatitis, the liver disease formerly known as NASH). FDA Fast Track designation specifically for MASH is the regulatory feather in this drug's cap. Not yet approved. The MASH-focused development is what differentiates Survodutide commercially from the mostly weight-loss-focused dual and triple agonists.

Why this peptide is on people's radar

Survodutide is the third major GLP-1/glucagon dual agonist to reach Phase 3, alongside Mazdutide (Eli Lilly / Innovent, approved in China) and the dual-agonist component of Eli Lilly's retatrutide (which adds GIP to make it a triple agonist). What differentiates Survodutide commercially is the focus on metabolic dysfunction-associated steatohepatitis (MASH), the liver-disease end of the metabolic-syndrome spectrum, formerly called NASH.

The mechanistic case for dual GLP-1/glucagon agonism in MASH is unusually clean. GLP-1 reduces appetite (driving weight loss, which improves fatty liver). Glucagon receptor activation specifically increases hepatic fat burning, it's the only mechanism among the major weight-loss drug classes that directly targets liver fat. For patients with MASH, that combination is theoretically more directly liver-active than tirzepatide (GLP-1 + GIP) or pure GLP-1 monotherapy.

Survodutide received FDA Fast Track designation for MASH in 2024, a regulatory acknowledgment that the disease has unmet need and the drug has potential. Phase 2 data in MASH showed reductions in liver fat content and improvements in fibrosis markers, supporting the MASH-focused development path. The chronic weight management Phase 3 (SYNCHRONIZE-1) is running alongside.

For U.S. readers: Survodutide is the dual agonist most likely to reach Western markets through MASH first, with weight-management approval likely following. Whether it gets approved on a similar timeline to retatrutide depends on the SYNCHRONIZE program readouts and FDA review pace.

What people are usually trying to do with it

People reading about Survodutide are usually focused on:

  • Following the next generation of GLP-1-class metabolic drugs
  • Tracking the MASH (formerly NASH) treatment landscape, there are very few approved options
  • Understanding dual-agonist mechanism (GLP-1 + glucagon) compared to dual GIP variants
  • Evaluating treatment options if they have metabolic-syndrome-related liver issues
  • Comparing emerging options to tirzepatide and retatrutide

What the science actually shows

Plain-English summary:

Phase 2 chronic weight management

Phase 2 trial reported up to ~19% mean weight loss at the highest dose over 46 weeks in adults with overweight or obesity, competitive with tirzepatide-class numbers and supporting Phase 3.1

Phase 2 MASH (formerly NASH)

Phase 2 in adults with MASH reported reductions in liver fat content, improvements in fibrosis markers, and weight loss. The hepatic-fat reductions are the differentiating data versus pure GLP-1s.2

FDA Fast Track designation for MASH

FDA Fast Track designation granted in 2024 specifically for the MASH indication. Reflects unmet need in MASH and the drug's mechanistic fit.3

SYNCHRONIZE Phase 3 program

Phase 3 program is running for both weight management (SYNCHRONIZE-1) and MASH (SYNCHRONIZE-MASH). Readouts expected through 2025–2027.

What hasn't been demonstrated

FDA approval. Long-term cardiovascular outcomes. Whether the MASH-specific advantage in Phase 2 (vs pure GLP-1s) holds up at scale. Direct head-to-head comparison with tirzepatide or retatrutide.

The honest read

What's solid:

The Phase 2 data is real and competitive with the dual-agonist class. The mechanistic rationale for dual GLP-1/glucagon in MASH is unusually clean. The Fast Track designation reflects a real clinical need and a real chance to meet it. Boehringer's regulatory and commercial maturity are well-established.

What's still being worked out:

Phase 3 readouts. Whether the MASH-specific advantage scales. How Survodutide will position commercially against tirzepatide (already approved) and retatrutide (likely to approve before Survodutide). The MASH approval pathway is differentiated; the weight-management approval pathway is more crowded.

What's hyped beyond the evidence:

Treating Survodutide as available, it isn't. "Compounded survodutide" being marketed online is not the FDA-approved drug (which doesn't exist) and isn't operating under any manufacturing oversight. Also: framing the MASH mechanism as proven clinical advantage at scale. Phase 2 data is encouraging; Phase 3 readouts will determine whether the differentiation holds.

Things to know if you're looking into it

  • Investigational status: Phase 3. Not FDA-approved. SYNCHRONIZE program readouts expected through 2025–2027.
  • FDA Fast Track for MASH: the regulatory differentiator. Survodutide may reach U.S. approval through MASH before weight management.
  • Dual mechanism: GLP-1 + glucagon, same combination as Mazdutide, different from tirzepatide (GLP-1 + GIP) and retatrutide (GLP-1 + GIP + glucagon).
  • How it would be used: a once-weekly subcutaneous injection. Standard GLP-1-class titration schedule.
  • Side-effect profile: primarily gastrointestinal, nausea, diarrhea, decreased appetite. The glucagon component adds modest cardiovascular monitoring considerations.
  • Compounded versions are not the drug: any product marketed as "compounded survodutide" is not the FDA-approved drug and isn't subject to manufacturing oversight.
  • Specific dosing schedule, mechanism, and trial detail: all in the "Want to go deeper?" section below.

What people often ask

Is Survodutide approved?

No. Currently in Phase 3 development for both chronic weight management and MASH. FDA Fast Track designation for MASH was granted in 2024.

How does it compare to Mazdutide?

Same general mechanism class (GLP-1 + glucagon dual agonist). Different developers (Survodutide is Boehringer Ingelheim / Zealand Pharma; Mazdutide is Eli Lilly / Innovent). Different markets (Survodutide targets U.S./EU; Mazdutide is approved in China). Survodutide's Phase 2 weight-loss numbers (~19%) were higher than Mazdutide's Phase 3 (~14–18%), though direct comparison requires Phase 3 data.

What's MASH and why does it matter here?

Metabolic dysfunction-Associated Steatohepatitis, the more severe end of fatty liver disease, formerly called NASH (nonalcoholic steatohepatitis). It's a major cause of liver damage, cirrhosis, and liver cancer in adults with metabolic syndrome. Treatment options have been very limited until recently. The glucagon-receptor component of Survodutide directly targets liver fat, which is why MASH is its differentiating use case.

How does it compare to retatrutide or tirzepatide for weight loss?

Phase 2 data: Survodutide ~19%, retatrutide ~24% Phase 2, tirzepatide ~22.5% Phase 3. So Survodutide is competitive but probably won't lead the pack on raw weight-loss numbers. The MASH angle is where it stands out commercially.

What about side effects?

Primarily GI, same class effect as the GLP-1 family. The glucagon component adds modest considerations around heart rate and blood pressure that the trials track carefully.

When might it be approved?

Depends on Phase 3 readouts. MASH Fast Track could mean MASH approval first (potentially 2026–2027 if SYNCHRONIZE-MASH reads out well). Weight-management approval likely follows.

Can I get it now?

Through clinical trial enrollment. ClinicalTrials.gov has the SYNCHRONIZE trials searchable. Anything sold as "survodutide" outside trials isn't the FDA-approved drug and isn't operating under manufacturing oversight.

FDA and regulatory status

Status as of May 5, 2026: Investigational. Not FDA-approved. FDA Fast Track designation granted in 2024 for the MASH indication. Currently in Phase 3 trials (SYNCHRONIZE program) for both chronic weight management and MASH. Status updates land here when they happen.

Want to go deeper? Mechanism, the SYNCHRONIZE program, dosing, side-effect profile, and references.

Background and development

Survodutide (development code BI 456906) is a synthetic peptide GLP-1/glucagon dual agonist. Originally developed by Zealand Pharma and Boehringer Ingelheim under a strategic partnership. Boehringer leads the clinical-development program, with Zealand Pharma retaining royalty rights. Phase 1 and Phase 2 trials demonstrated weight-loss and metabolic efficacy in adults with overweight, obesity, type 2 diabetes, and MASH. FDA Fast Track designation for MASH granted in 2024.

Mechanism of action

GLP-1 receptor activation

Same receptor as semaglutide. Slows gastric emptying, suppresses appetite via central nervous system effects, supports glucose-dependent insulin secretion.

Glucagon receptor activation

Increases basal energy expenditure, reduces hepatic fat content, and influences fat metabolism. The hepatic-fat-reducing effect is why MASH is a particularly suitable indication.

Why MASH is the regulatory differentiator

MASH involves both metabolic dysfunction (which GLP-1 addresses) and liver fat accumulation (which glucagon-receptor activation directly targets). The dual mechanism is unusually well-matched to the disease pathology, which the FDA Fast Track designation reflects.

Half-life and dosing

Plasma half-life supports once-weekly subcutaneous administration.

The SYNCHRONIZE Phase 3 program

Phase 3 program with parallel readouts in different indications:

  • SYNCHRONIZE-1: Phase 3 chronic weight management trial in adults with overweight or obesity. Readout expected through 2025–2027.
  • SYNCHRONIZE-MASH: Phase 3 trial in adults with biopsy-confirmed MASH and significant fibrosis. The Fast Track-eligible trial.
  • Type 2 diabetes program: additional Phase 3 trials in T2D populations.

Side effects and safety profile

The most common adverse events in trials have been gastrointestinal, nausea, vomiting, diarrhea, decreased appetite, common to the GLP-1 class. The glucagon-receptor component introduces additional considerations:

  • Modest heart-rate increases observed in some patients
  • Blood pressure tracking
  • Liver enzyme considerations (relevant for the MASH population)

Discontinuation rates due to adverse events have been broadly comparable to GLP-1 monotherapy at similar weight-loss-dose levels.

References

  1. le Roux CW, Steen O, Lucas KJ, et al. (2024). "Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial." The Lancet Diabetes Endocrinol, 12(2), 162–173. PubMed
  2. Sanyal AJ, Lopez P, Lawitz E, et al. (2024). "Survodutide for metabolic dysfunction-associated steatohepatitis." N Engl J Med. PubMed
  3. Boehringer Ingelheim. "FDA Fast Track designation for survodutide in MASH." Press release, 2024. Boehringer Ingelheim
  4. Zealand Pharma / Boehringer Ingelheim. "SYNCHRONIZE Phase 3 program." Press releases and SEC filings, 2024–2026.
  5. ClinicalTrials.gov. SYNCHRONIZE program registry. ClinicalTrials.gov
For educational and research purposes only. This is not medical advice. Survodutide is investigational and not FDA-approved as of May 2026. FDA Fast Track designation for MASH does not equal approval. Compounded versions are not the FDA-approved drug. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.